emailEmail this page

printPrint this page

phoneFOR MORE INFORMATION ON OUR PRODUCTS, CONTACT A SALES REPRESENTATIVE at 800.388.8884, press 2.

Recommended Wolters Kluwer Health Products

FACTS & COMPARISONS®

CLIN-EGUIDE™

Duplicate Therapy Database™

Improves Clinical Outcomes by Avoiding Unnecessary Therapeutic Duplication

PREVENTS DRUG DUPLICATION
Duplicate Therapy Database™ equips health care providers with accurate, timely alerts to potential duplications in drug therapy. Information in the database is drug-specific, comprehensive and Screens for drugs with similar primary indications or active ingredients.

FEATURES

  • Therapeutic duplications for products used for single and multiple therapeutic purposes
  • Ingredient duplications for single and multiple ingredient products
  • OTC medication duplications
  • Codes identifying duplication class, be it an ingredient, mechanism of action or therapeutic indication
  • Significance codes to indicate presence of abuse potential
  • Duplication Allowance indicator to specify the number of acceptable duplications before providing an alert

BENEFITS

FOR HEALTH CARE FACILITIES

  • Supports Drug Utilization Review (DUR)
  • Identifies duplications related to ingredients, actions or indications
  • Screens for drug duplications with abuse potential
  • Improves both clinical and financial outcomes by avoiding toxic or unnecessary therapies
  • Reduces risks by protecting against unintentional drug duplication associated with the combined use of prescription and OTC medications
  • Enhances the safety of patients being treated by multiple physicians
  • Click here to download the PDF

FOR HEALTH CARE PROVIDERS

  • Supports Drug Utilization Review (DUR)
  • Identifies duplications related to ingredients, actions or indications
  • Screens for drug duplications with abuse potential
  • Improves both clinical and financial outcomes by avoiding toxic or unnecessary therapies
  • Reduces risks by protecting against unintentional drug duplication associated with the combined use of prescription and OTC medications
  • Enhances the safety of patients being treated by multiple physicians
  • Click here to download the PDF

FOR PAYERS

  • Supports Drug Utilization Review (DUR)
  • Identifies duplications related to ingredients, actions or indications
  • Screens for drug duplications with abuse potential
  • Improves both clinical and financial outcomes by avoiding toxic or unnecessary therapies
  • Reduces risks by protecting against unintentional drug duplication associated with the combined use of prescription and OTC medications
  • Enhances the safety of patients being treated by multiple physicians
  • Click here to download the PDF

FOR PHARMACISTS

  • Supports Drug Utilization Review (DUR)
  • Identifies duplications related to ingredients, actions or indications
  • Screens for drug duplications with abuse potential
  • Improves both clinical and financial outcomes by avoiding toxic or unnecessary therapies
  • Reduces risks by protecting against unintentional drug duplication associated with the combined use of prescription and OTC medications
  • Enhances the safety of patients being treated by multiple physicians
  • Click here to download the PDF
Medi-Span®, a part of Wolters Kluwer Health, is the leading provider of prescription drug information and drug interactions databases for thousands of health care professionals worldwide. With more than 30 years experience, Medi-Span continues to offer authoritative adverse drug reactions information and drug contraindications data in a variety of formats, including clinical decision support and disease suite modules, application programming interfaces and stand-alone software applications. Price Rx®, a Medi-Span product, offers drug pricing information for drug pricing analysis, formularly management and drug utilization review. In conjunction with superior implementation and experienced customer support, the Medi-Span product line is the perfect choice for those needing accurate, trusted drug data that easily integrates into existing software applications.